Abstract:
The present invention provides a method of sterilizing a pharmaceutical composition, the method comprising providing a sterilization system including heat exchanger means for elevating and then lowering the temperature of the fluid in a time period; measuring temperature at an input of the heat exchanger means, measuring temperature at an output of the heat exchanger means and measuring temperature at least one point in the heat exchanger means intermediate to the input and output; calculating a coefficient of heat transfer for the sterilization system using the temperature measurements; calculating a degree of sterilization (Fo) using the coefficient; and adjusting the temperature of the heat exchanger means to minimize degradation of the pharmaceutical composition while maintaining an acceptable degree of sterilization.
Abstract:
The attachment of H. influenzae to human cells, such as oropharyngeal cells, may be inhibited by native human beta -casein, a recombinant form of human beta -casein, and hydrolysates of both. The human beta -casein or hydrolysate may be contained in a liquid enteral nutritional product such as an infant formula. The enteral nutritional product may be used, for example, in the prevention and treatment of otitis media in infants. The human beta -casein or hydrolysate may also be administered as a throat spray or nasally using drops or a spray.
Abstract:
A push button flow stop is mounted on a disposable infusion pumping cassette provided for use with a drug infusion pump. The flow stop is operative to enable or to block fluid flow through the cassette in a first mode and to monitor fluid pressure in the cassette in a second mode.
Abstract:
This apparatus is intended for maintaining the patency of an indwelling vein access device (14). The apparatus includes a vein access device (14) such as a catheter (14) connected to a self-energized container (12) having a capacity to deliver an infusate to the vein access device (14) at a flow rate of approximately 0.01-1.0 ml per hour.
Abstract:
An enteral nutritional product and method of treatment for a person having ulcerative colitis contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.
Abstract:
The invention relates to the milk of a transgenic non-human mammal. The milk is characterized in that it contains heterologous components produced as the secondary gene products of a heterologous gene contained in the genome of the transgenic non-human mammal. The heterologous gene encodes a heterologous catalytic entity such as a human enzyme selected from the group consisting of glycosyltransferases, phosphorylases, hydroxylases, peptidases and sulfotransferases. Especially useful in the practice of the invention are human glycosyltransferases. The desired heterologous components include oligosaccharides, glycoconjugates. The oligosaccharides and glycoconjugates may be isolated from the milk of the transgenic mammals and used in the preparation of pharmaceuticals, diagnostic kits, nutritional products and the like. The whole transgenic milk may also be used to formulate nutritional products that provide special advantages. The transgenic milk may also be used in the production of specialized enteral nutritional products.
Abstract:
An assay to simultaneously detect the presence of HIV-1 antibody and/or HIV-2 antibody in a test sample is disclosed. The analytes are captured on either the same or different solid phases, and the presence of the analytes is determined by detecting a signal generated by using a cocktail of synthetic and recombinant antigen-containing indicator reagents.
Abstract:
Mammalian expression systems for the production of HCV E1-E2 fusion proteins. Such expression systems provide high yields of HCV proteins extracellularly, and enable the development of diagnostic, vaccine and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.
Abstract:
An improved enteral nutritional formula containing nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adjuncts such as activated sugars) at a level of at least 10 mg/100 Kcal (kilocalorie) of formula is disclosed. The formula comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) nucleotide equivalents at specific levels and ratios. The invention also discloses novel methods of production and analytical techniques. This invention also provides a dietary formula that enhances the immune system and alleviates diarrhea.